Anticoagulant Reversal in Gastrointestinal Bleeding: Review of Treatment Guidelines

Background Patients receiving anticoagulant therapies, such as vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs), commonly experience gastrointestinal (GI) bleeding as a complication and may require anticoagulant reversal prior to endoscopic treatment. Anticoagulant reversal agents include prothrombin complex concentrates (PCCs; including 3 or 4 coagulation factors), plasma, vitamin K, and target-specific DOAC reversal agents (e.g., idarucizumab and andexanet alfa). Aim To review current US, as well as international, guidelines for anticoagulant reversal agents in patients on VKAs or DOACs presenting with GI bleeding prior to endoscopy, guideline-based management of coagulation defects, timing of endoscopy, and recommendations for resumption of anticoagulant therapy following hemostasis. Supporting clinical data were also reviewed. Methods This is a narrative review, based on PubMed and Internet searches reporting GI guidelines and supporting clinical data. Results GI-specific guidelines state that use of reversal agents should be considered in patients with life-threatening GI bleeding. For VKA patients presenting with an international normalized ratio > 2.5, guidelines recommend PCCs (specifically 4F-PCC), as they may exhibit greater efficacy/safety compared with fresh frozen plasma in reversal of VKA-associated GI bleeding. For DOAC patients, most guidelines recommend targeted specific reversal agents in the setting of GI bleeding; however, PCCs (primarily 4F-PCC) are often listed as another option. Resumption of anticoagulant therapy following cessation of GI bleeding is also recommended to reduce risks of future thromboembolic complications. Conclusions The utility of anticoagulant reversal agents in GI bleeding is recognized in guidelines; however, such agents should be reserved for use in truly life-threatening scenarios..

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:66

Enthalten in:

Digestive diseases and sciences - 66(2021), 11 vom: 06. Jan., Seite 3698-3714

Sprache:

Englisch

Beteiligte Personen:

Milling, Truman J. [VerfasserIn]
Refaai, Majed A. [VerfasserIn]
Sengupta, Neil [VerfasserIn]

Links:

Volltext [lizenzpflichtig]

BKL:

44.87$jGastroenterologie

Themen:

Andexanet alfa
Anticoagulants
Idarucizumab
Prothrombin complex concentrates

Anmerkungen:

© Springer Science+Business Media, LLC, part of Springer Nature 2021

doi:

10.1007/s10620-020-06728-y

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

OLC2128069866

Zugang & Verfügbarkeit




Zugehörige Publikationen/Bände

    Haven't found what you're looking for?